Omicron 'less severe but just as threatening,' expert warns amid testing gaps

In early January 2022, as Britain watched case numbers appear to drop, a leading epidemiologist offered a cautionary reading of the data: the numbers themselves might be lying. Graham Medley, a professor of infectious disease modelling at the London School of Hygiene and Tropical Medicine, told the BBC that the apparent decline in Covid infections was likely an artifact of the testing system buckling under strain. The Christmas and New Year holidays had disrupted reporting. Testing capacity had hit its limits. What looked like good news on a chart might simply reflect the fact that fewer people were being counted.

The real picture, Medley suggested, remained murky. Hospital admissions were still running high. Whether they would climb further or begin to fall was, he said plainly, unknown. The virus itself had changed—Omicron was demonstrably less severe than the Delta variant that had dominated the previous months—but severity was only part of the equation. What made Omicron threatening was its extraordinary ability to spread. It moved through populations so quickly that even a milder illness, multiplied across millions of infections, could still overwhelm healthcare systems and disrupt ordinary life.

This distinction mattered because it shaped how the country should think about what came next. Medley acknowledged what officials and the public alike were beginning to sense: Covid could not remain an emergency forever. At some point, the acute crisis posture would have to end. But he pushed back against the idea that this transition would happen on a particular day, announced by a government minister. Instead, the shift from emergency to endemic disease would be gradual, a slow fade rather than a switch flipped. The virus would linger, become routine, settle into the background of ordinary illness.

Once that transition was complete, Medley argued, the calculus for managing the disease would shift fundamentally. Governments would move from trying to prevent hospitals from being overwhelmed to making cost-benefit decisions about public health in the conventional sense. This was how policy worked for influenza, for measles, for other diseases that had moved from crisis to routine. Some diseases warranted annual vaccination campaigns. Others did not. The decision depended on weighing effectiveness, cost, and risk.

The question of free testing and free vaccination hung over this conversation. As the emergency phase wound down, would these remain available to everyone? Medley did not say they should end, but he suggested that decisions about them would increasingly resemble decisions about other public health tools—weighed against other priorities, subject to budget constraints, made through the normal machinery of government policy rather than through crisis protocols. He noted that free testing had allowed people to manage their own risk since July, when submissions had held steady at just under a thousand a day. That stability suggested people were using the tools available to them to make their own choices about exposure and isolation.

What remained unresolved was the timing and the shape of that transition. The data was too uncertain to say when the emergency phase would truly end. Hospital admissions could still move in either direction. Testing gaps meant the actual spread of the virus was harder to track than the official numbers suggested. In that fog of incomplete information, Medley's message was clear: the crisis would not end with a declaration. It would end with a gradual recognition that it already had.